News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,649 Results
Type
Article (39055)
Company Profile (279)
Press Release (646315)
Section
Business (203868)
Career Advice (1991)
Deals (35364)
Drug Delivery (85)
Drug Development (80800)
Employer Resources (168)
FDA (16088)
Job Trends (14805)
News (344550)
Policy (32437)
Tag
Academia (2530)
Alliances (49088)
Alzheimer's disease (1229)
Approvals (16020)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11538)
Biotechnology (200)
Breast cancer (120)
Cancer (1087)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (234)
Clinical research (64252)
Collaboration (388)
Compensation (200)
COVID-19 (2530)
C-suite (94)
Data (1126)
Diabetes (152)
Diagnostics (6139)
Earnings (84821)
Employer resources (146)
Events (109491)
Executive appointments (310)
FDA (16627)
Funding (353)
Gene therapy (178)
GLP-1 (577)
Government (4325)
Healthcare (18669)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16304)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19141)
Metabolic disorders (402)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1481)
Obesity (232)
Opinion (180)
Patents (102)
People (56275)
Phase I (19955)
Phase II (28303)
Phase III (21099)
Pipeline (458)
Postmarket research (2554)
Preclinical (8494)
Radiopharmaceuticals (236)
Rare diseases (219)
Real estate (5890)
Regulatory (21525)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1302)
Startups (3562)
United States (13500)
Vaccines (549)
Weight loss (168)
Date
Today (80)
Last 7 days (669)
Last 30 days (3728)
Last 365 days (35687)
2024 (32752)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46542)
2018 (35020)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37123)
Australia (6059)
California (3331)
Canada (1295)
China (252)
Colorado (147)
Connecticut (153)
Europe (79507)
Florida (461)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2611)
Michigan (158)
Minnesota (273)
New Jersey (957)
New York (964)
North Carolina (702)
Northern California (1481)
Ohio (139)
Pennsylvania (847)
South America (1091)
Southern California (1302)
Texas (465)
Utah (90)
Washington State (362)
685,649 Results for "visterra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc., ; Otsuka Pharmaceutical, Co. Ltd. ; and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy.
February 16, 2024
·
7 min read
Drug Development
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.
November 2, 2023
·
8 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
August 1, 2024
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Boston Scientific Closes Acquisition of Axonics, Inc.
November 15, 2024
·
5 min read
Press Releases
TearSolutions, Inc. Secures $3M Series B Funding
November 22, 2024
·
1 min read
Press Releases
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
November 21, 2024
·
4 min read
Press Releases
Progyny, Inc. to Present at Jefferies London Healthcare Conference
November 14, 2024
·
1 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
1 of 68,565
Next
